WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 2078% more annual revenue ($56.69B vs $2.60B). NVS leads profitability with a 22.5% profit margin vs 10.6%. AVAH trades at a lower P/E of 10.7x. AVAH earns a higher WallStSmart Score of 61/100 (C+).

AVAH

Buy

61

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 5.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHSignificantly Overvalued (-70.9%)

Margin of Safety

-70.9%

Fair Value

$4.67

Current Price

$12.41

$7.74 premium

UndervaluedFair: $4.67Overvalued
NVSSignificantly Overvalued (-53.7%)

Margin of Safety

-53.7%

Fair Value

$93.40

Current Price

$145.46

$52.06 premium

UndervaluedFair: $93.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH3 strengths · Avg: 9.3/10
P/E RatioValuation
10.7x10/10

Attractively priced relative to earnings

Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

EPS GrowthGrowth
38.5%8/10

Earnings expanding 38.5% YoY

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$271.25B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

AVAH3 concerns · Avg: 2.3/10
Price/BookValuation
9.4x4/10

Trading at 9.4x book value

Altman Z-ScoreHealth
0.952/10

Distress zone — elevated risk

Debt/EquityHealth
5.241/10

Elevated debt levels

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.312/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : AVAH

The primary concerns for AVAH are Price/Book, Altman Z-Score, Debt/Equity. Debt-to-equity of 5.24 is elevated, increasing financial risk.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

AVAH carries more volatility with a beta of 1.97 — expect wider price swings.

AVAH is growing revenue faster at 13.7% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AVAH scores higher overall (61/100 vs 51/100) and 13.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?